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[2,5-dimethylfuran]-protected maleimides were placed at both internal positions and the 3'-end of 
oligonucleotides making use of solid-phase synthesis procedures. A new phosphoramidite derivative and 
a new solid support incorporating the protected maleimide moiety were prepared for this purpose. In all 
cases maleimide deprotection (retro-Diels–Alder reaction) followed by reaction with thiol-containing 
compounds afforded the target conjugate. 10 
Introduction 
Derivatization of oligonucleotides by covalent attachment of a 
non-oligonucleotide moiety, usually referred to as conjugation, is 
a common alternative to improve oligonucleotides performance 
in biological assays and suitability for therapeutic applications 15 
(1). 3'-Modification is known to impart protection to the most 
ubiquitous nucleases, namely 3'-exonucleases (2), and 
conjugation often improves oligonucleotides' cell permeation 
properties. 
In general there is a rationale on the decision as to which moiety 20 
is to be linked to the oligonucleotide chain, but the linking site 
and the linkage type are most often dictated by the chemically 
available tools (resins or phosphoramidite derivatives 
commercially available, derivatives synthesized at the laboratory 
carrying out the study, etc.). Even though changes in the 25 
constitution of the conjugate will likely have an influence on the 
outcome of biological assays, there is not much information 
available on this type of structure-activity correlation. 
Indeed, there are reports showing the outcome of such changes. It 
has been described, for instance, that the immune stimulating 30 
properties of conjugates in which a 28-mer !-amyloid peptide 
was attached to an oligonucleotide varied depending on whether 
the peptide was linked to either the 5'- or the 3'-end (3). It has 
also been reported that the stability of thiol-maleimide adducts 
may vary depending on the "external" environment, such as the 35 
presence of inorganic anions (4) or reducing agents (thiols) (5), 
but also depending on the structure of the conjugate itself (6). In a 
recent piece of work (6), Junutula and co-workers have shown 
that the stability and activity of antibody-drug conjugates varies 
depending on whether the conjugation site is placed in a highly 40 
solvent accessible and positively charged local environment, or in 
a partially accessible and neutral local environment. 
In a different context, but also showing the importance of 
conjugates' constitution, an interesting example is the use of DNA 
as a ruler (7), which shows that the covalent attachment of 45 
peptides to different positions of the chain can provide 
information on the spatial distribution of protein binding sites (7, 
see references therein for other examples of applications of 
complex molecular structures). 
Oligonucleotide conjugates can be assembled making use of 50 
solid-phase technologies when suitably derivatized building 
blocks of solid supports are available (8). Convergent solution 
synthesis is the other alternative. In this case the two moieties to 
be linked must be derivatized with functional groups ideally 
reacting regio- and chemoselectively, exploiting the so-called 55 
click chemistry (9). The par excellence click reaction is the Cu(I)-
catalyzed azide-alkyne cycloaddition, but well-performing click 
reactions can exploit other functional groups as well. Maleimides 
are examples of useful functional units, since they can be 
involved in two different click reactions, the Michael-type 60 
reaction with thiols and the Diels-Alder cycloaddition. 
For many years the most common alternative for the 
derivatization of oligonucleotides with a maleimide has been the 
reaction, in solution, of bifunctional compounds incorporating a 
carboxylic acid and a maleimide with the amine group of amino-65 
derivatized oligonucleotides (10). The problem with this 
methodology is that amide formation does not always take place 
in high yield. Yet, attachment of the maleimide-containing 
bifunctional compound to amino-derivatized resin-linked 
oligonucleotides is not an alternative, because the ammonia 70 
treatment that removes oligonucleotide protecting groups 
degrades the maleimide (11). 
Solid-phase assembly is only possible provided that the 
maleimide is protected and remains stable to the ammonia 
deprotection treatment. We have recently described that 75 
maleimide building blocks fulfilling this requirement can be 
obtained by reaction with 2,5-dimethylfuran, followed by 
removal of the ammonia-labile endo adduct (12). Bifunctional 
compounds containing a protected maleimide (exo adduct) and 
either phosphoramidite (1) or carboxyl (2) groups (Figure 1) can 80 
be used for the on-resin assembly of maleimido-oligonucleotides. 
Compound 1 has two advantages over 2. On the one hand, that it 
can be incorporated after elongation of the oligonucleotide chain 
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using the same chemistry as for all nucleosides. On the other, it is 
not necessary to assemble amine-derivatized resin-linked 
oligonucleotides to which 2 must be coupled by forming an 
amide bond. Even though this type of reactions takes place on a 
solid matrix, which allows large excesses of the activated 5 
carboxyl-containing species to be added, coupling yields have 
been described as poorly reproducible and not always fully 
satisfactory (13). 
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Figure 1. Structures of the [protected maleimido]-containing derivatives 10 
previously used in the synthesis of maleimido-oligonucleotides. 
Incorporation of a protected maleimido unit after oligonucleotide 
elongation using standard nucleoside-3'-phosphoramidite 
derivatives, followed by deprotection with ammonia and heating 
to provide the free maleimide (retro-Diels–Alder reaction), 15 
affords 5'-maleimido-oligonucleotides. Chain elongation with 
nucleoside-5'-phosphoramidites might allow 3'-maleimido-
oligonucleotides to be assembled, but these derivatives are much 
more expensive than standard nucleoside-3'-phosphoramidite. 
Since, as described above, it is important to have access to 20 
conjugates with different structures, we decided to prepare a new 
phosphoramidite building block allowing the maleimide unit to 
be placed at internal positions of the oligonucleotide sequence (in 
fact at any position of the chain), and a new solid matrix 
incorporating the protected maleimide moiety that is suitable for 25 
the synthesis of 3'-maleimido-oligonucleotides making use of 3'-
phosphoramidite derivatives. In this manuscript we describe their 
synthesis and their use in the preparation of maleimido-
oligonucleotides. These maleimido-oligonucleotides were reacted 
with thiols to assess the functionality of the maleimides. 30 
Results and discussion 
The synthesis of building block 5 and solid support 7 is 
summarized in Scheme 1. Both incorporate a DMT-protected 
hydroxyl to allow for further elongation of the chain. The two 
compounds 5 and 7 derive from common precursor 4, which has 35 
the advantage that preparation of 4 provides a stock of a product 
from which either 5 or 7 can be obtained in one or two steps. 
For the synthesis of 4, the amino group of L-serinol, more 
nucleophilic than the hydroxyl groups, was derivatized first. 
Reaction between 2 (exo adduct), a carbodiimide and 40 
pentafluorophenol provided the pentafluorophenyl ester of 2, and 
this active ester reacted with L-serinol to form the amide with no 
need to protect the hydroxyl groups. Then, one of the hydroxyl 
groups of the resulting compound (3) was protected by reaction 
with DMT-Cl. Use of a smaller amount of DMT-Cl (0.9 equiv) 45 
with respect to 3 facilitated formation and isolation of 4 as the 
main product. Phosphitylation of 4 afforded phosphoramidite 5, 
while reaction of 4 with succinic anhydride and incorporation of 
the resulting 6 onto LCAA-CPG provided support 7. 
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Scheme 1. Synthesis of [protected maleimido]-derivatized building block 
5 (a) and solid support 7 (b). 
Derivatives 5 and 7 were used in the synthesis of two maleimido-
oligonucleotides, 9 and 12 (Scheme 2). In both cases chain 
elongation proceeded smoothly, showing that the two derivatives 55 
behaved as standard building blocks. The [protected maleimido]-
oligonucleotides (8 and 11) obtained after reaction with ammonia 
at room temperature were purified by HPLC (Figure 2) and 
characterized by mass spectrometry. 
Maleimide deprotection was carried out using the method that 60 
had performed better in our previous work (12, 14), namely 
heating a suspension of the oligonucleotide in anh. toluene at 90 
oC for 4 h. Maleimide deprotection yields were above 90 %, as 
assessed by HPLC analysis of the crudes (Figure 3). 
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Scheme 2. Synthesis of [protected maleimido]-oligonucleotides, 
maleimido-oligonucleotides and conjugates. 
 5 
Figure 2. Crude 5'dGTAC-[protected maleimido monomer]-TAGC 8 (a) 
and dT5-3'[protected maleimide] 11 (b). 
 
Figure 3. Crude 5'dGTAC-[maleimido monomer]-TAGC 9 (a) and dT5-
3'[maleimide] 12 (b). 10 
Finally, it was verified that reversal of the Diels-Alder 
dimethylfuran-maleimide cycloadduct afforded oligonucleotides 
with appending fully reactive maleimides. For this purpose, 
maleimido-oligonucleotides 9 and 12 were reacted with thiol-
containing compounds, as shown in Scheme 2. Michael-type 15 
thiol-maleimide reactions yielded the target conjugates, as 
confirmed by mass spectrometric analysis of the product 
corresponding to the main peak of the HPLC trace of the crude 
(Figure 4). The maleimide moiety linked to the 3'-end of the 
oligonucleotide thoroughly reacted with two primary thiols, those 20 
of biotin-SH and glutathione, to yield conjugates 13 and 14, 
respectively (Figure 4b,c). Likewise, reaction between the 
maleimide placed at an internal position and the secondary thiol 
of thiocholesterol, somehow more demanding because the 
reaction groups were more hindered, cleanly furnished conjugate 25 
10 (Figure 4a). 
 
Figure 4. Crude conjugates 10 (a), 13 (b) and 14 (c). 
Conclusions 
In summary, a phosphoramidite derivative and a solid support 30 
incorporating 2,5-dimethylfuran-protected maleimide moieties 
were synthesized from a common precursor (4), obtained from L-
serinol. Both were satisfactorily used in the preparation of 
maleimido-oligonucleotides that subsequently underwent addition 
of thiols, thus proving that maleimide deprotection affords 35 
reactive maleimides. This new building block and resin expand 
the repertoire of possibilities allowing the derivatization of 
oligonucleotides at different positions, and thus give access to 
differently decorated oligonucleotide chains. 
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Experimental 
General 
Nucleoside phosphoramidites (dAPac, dCAc, dGDmf and dT), CPG 
supports, and oligonucleotide synthesis reagents were from either 
Link Technologies, Glen Research Corporation or Applied 5 
Biosystems. [Protected maleimido]-propanoic acid (2, exo 
adduct) was prepared as previously described (12). Biotin-SH 
was prepared following described procedures (14). Glutathione 
and thiocholesterol were from Sigma-Aldrich. Acid-free DCM 
was obtained by filtration through basic alumina. 10 
TLC was carried out on silica gel plates 60 F254 from Merck. 
Samples were lyophilized in a FreezeMobile Virtis instrument. 
The amount of free thiols in thiol-containing compounds was 
quantified by the Ellman test, as described in the Supporting 
Information of reference 12. 15 
Oligonucleotide synthesis. Oligonucleotide chains were 
assembled in a 3400 ABI automatic synthesizer at the 1 µmol 
scale, using standard phosphoramidite synthesis cycles. 
Phosphoramidite 5 and solid support 7 were used as any standard 
reagent. After chain elongation, treatment with concd. aq. 20 
ammonia at room temperature (1 h in case of homo-dT oligomer 
11; 8 h when all the bases were present) removed protecting 
groups from the oligonucleotide. After filtration and washing, 
ammonia was evaporated under reduced pressure, and the sample 
lyophilized. Oligonucleotides were purified by reversed-phase 25 
HPLC, quantified by UV spectroscopy (! = 260 nm), and 
characterized by mass spectrometry. 
Maleimide deprotection by heating in toluene. The [protected 
maleimido]-containing oligonucleotide was dried by 
coevaporation with anh. toluene (3-4 "), and a new batch of anh. 30 
toluene was added (the amount that would be required to obtain a 
25 µM solution). The mixture was heated 90 ºC, toluene was 
removed under reduced pressure, and the crude was dissolved in 
water for HPLC analysis and mass spectrometric characterization. 
The crude was typically used at the subsequent conjugation step 35 
without any purification. 
General procedure for Michael-type conjugation reactions. 
Aliquots of aqueous solutions containing the required amounts of 
maleimido-containing oligomer and the corresponding thiol-
containing compound (5 to 10-fold molar excess) were mixed, 40 
and the mixture was diluted with 0.5 M triethylammonium 
acetate, pH = 7.8-7.9 (final concentration of oligomer: 50-150 
µM). The mixture was stirred at room temperature under an Ar 
atmosphere. Reaction crudes were analyzed by HPLC. 
Conjugates were purified by HPLC and characterized by 45 
MALDI-TOF MS. 
Synthesis of conjugate 10: thiocholesterol (not soluble in water) 
was dissolved in THF, and the reaction was carried out in a 3:2 
(v/v) 0.5 M triethylammonium acetate (pH = 7.8)/THF mixture. 
 50 
HPLC. Reversed-phase HPLC analysis and purification was 
performed using analytical and semipreparative Waters or 
Shimadzu systems. Analysis and purification conditions were: 
Oligonucleotide analysis conditions: Kromasil C18 column (10 
µm, 100 Å, 250 " 4.0 mm) from Akzo Nobel; solvent A: 0.05 M 55 
triethylammonium acetate, solvent B: H2O/ACN 1:1 (v/v), 
gradient from 5 to 60 % of B in 30 min, flow: 1 mL/min, 
detection wavelength: 254 nm. 
Oligonucleotide purification conditions (semipreparative 
scale): Jupiter C18 column (10 µm, 300 Å, 250 " 10.0 mm) from 60 
Phenomenex, solvent A: 0.1 M triethylammonium acetate, 
solvent B: H2O/ACN 1:1 (v/v), gradient from 5 to 60 % of B in 
30 min, flow: 3 mL/min, detection wavelength: 260 nm. 
Cholesterol-containing conjugate analysis and purification 
conditions: Kromasil C4 column (10 µm, 100 Å, 250 " 4.6 mm) 65 
from Teknokroma, solvent A: 0.05 M triethylammonium acetate 
(pH = 7.0), solvent B: acetonitrile, flow: 1 mL/min, detection 
wavelength: 254 nm. After injection of the samples, the column 
was eluted for 5 min with 10% of B, followed by gradient from 
10 to 90 % of B in 25 min. Subsequently, the column was eluted 70 
for 10 min with 90% of B. 
Mass spectrometry. MALDI-TOF mass spectra were recorded 
on a 4800 Plus ABSciex instrument using reflector. 
Oligonucleotide and conjugates analysis conditions: 1:1 (v/v) 
2,4,6-trihydroxyacetophenone/ammonium citrate (THAP/CA), 75 
negative mode. ESI (low and high resolution) mass spectra were 
obtained using an LC/MSD-TOF spectrometer from Agilent 
Technologies. 
Synthesis of the [protected maleimido]-containing monomer 5 
and solid support 7. 80 
[Protected maleimido]-diol 3. 2,5-Dimethylfuran-protected 3-
maleimidopropanoic acid (2, 300 mg, 1.13 mmol), DIPC (177 
µL, 1.13 mmol) and pentafluorophenol (210 mg, 1.13 mmol) 
were dissolved in anh. DMF (N,N-dimethylformamide). After 30 
min stirring, serinol (90 mg, 0.942 mmol) was added to the 85 
mixture containing the activated form of the carboxyl group, and 
left to react at room temperature under an Ar atmosphere for 12 
h. The solvent was removed under reduced pressure, and the 
resulting crude was purified by silica gel column chromatography 
eluting with DCM (dichloromethane) and increasing amounts of 90 
MeOH (from 0 to 10 %). 3 was obtained as a white solid (318 
mg, quantitative yield). 
TLC (DCM/MeOH 4:1): Rf = 0.32; 1H NMR (CDCl3, 400 MHz): 
# 6.30 (s, 2H), 3.86-3.82 (m, 6H), 3.78 (td, J = 7.0, 3.8 Hz, 1H), 
3.02 (t, J = 6.0 Hz, 2H), 2.84 (s, 2H), 2.57 (t, J = 6.0 Hz, 2H), 95 
1.70 (s, 6H); 13C NMR (CDCl3, 101 MHz): # 174.8, 159.1, 140.9, 
87.9, 64.4, 52.6, 52.5, 35.6, 34.5, 16.0 ppm; HRMS (ESI, positive 
mode): m/z 339.1539, calcd. for C16H23N2O6 [M+H]+ 339.1551, 
m/z 361.1374, calcd. for C16H22N2O6Na [M+Na]+ 361.1370, m/z 
699.2834, calcd. for C32H44N4O12Na [2M+Na]+ 699.2848. 100 
DMT-O-[Protected maleimido]-diol 4. Compound 3 (318 mg, 
0.94 mmol) and DMT-Cl (293 mg, 0.85 mmol) was dissolved in 
anh. pyridine (10 mL). After 15 h stirring at room temperature 
under an Ar atmosphere, pyridine was removed under reduced 
pressure. The resulting crude was purified by silica gel column 105 
chromatography eluting with hexanes/DCM 1:1, increasing 
amounts of DCM (until 100 %) and DCM/AcOEt mixtures (up to 
7:3) always with triethylamine (4 %). The fractions containing 
the desired product were pooled, and after removing the solvent 
in vacuo were coevaporated with ACN to eliminate triethylamine 110 
traces, dissolved in acid-free DCM (25 mL) and washed with 
brine (3 " 25 mL). The organic phase was dried over anh. Na2SO4 
and taken to dryness. A white solid (4, 410 mg, 75 % yield) was 
obtained. 
TLC (DCM/MeOH 19:1): Rf = 0.33; 1H NMR (CDCl3, 400 MHz 115 
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CDCl3): # 7.39-7.19 (m, 9H), 6.83 (d, J = 8.9 Hz, 4H), 6.28 (s, 
2H), 5.98 (d, J = 7.6 Hz, 1H), 4.03 (tt, J = 9.2, 4.7 Hz, 1H), 3.84 
(dd, J = 13.8, 7.3 Hz, 2H), 3.79 (s, 6H), 3.70 (dd, J = 13.7, 7.0 
Hz, 2H), 3.29 (qd, J = 9.7, 4.8 Hz, 2H), 2.78 (dd, J = 1.4 Hz, 2H), 
2.47 (t, J = 6.6 Hz, 2H) 1.67 (s, 6H); 13C NMR (CDCl3, 101 5 
MHz): # 174.8, 170.1, 158.7, 144.6, 141.0, 135.7, 130.1, 128.1, 
127.1, 113.4, 87.8, 86.7, 63.6, 63.2, 55.4, 52.5, 51.7, 35.2, 34.2, 
29.8, 16.0 ppm; HRMS (ESI, positive mode): m/z 663.2672, 
calcd. for C37H40N2O8Na [M+Na]+ 663.2677, m/z 1303.5430, 
calcd. for C74H80N4O16Na [2M+Na]+ 1303.5462. 10 
DMT-O-[Protected maleimido]-diol phosphoramidite 5. 
Compound 4 (225 mg, 0.35 mmol) was dried by coevaporation 
with anh. ACN (3 " 1 mL), and dissolved in anh. DCM (1 mL). 
Triethylamine (1 mL, 7.17 mmol) and (2-
cyanoethoxy)chloro(diisopropylamino)-phosphine (83 µL, 0.37 15 
mmol) was added, and the mixture was reacted at room 
temperature for 1 h under an Ar atmosphere. This was followed 
by addition of DCM (25 mL) and extraction with 5 % NaHCO3 (2 
" 25 mL) and brine (1 " 25 mL). The organic phase was dried 
over Na2SO4 and the solvent was removed under vacuum, adding 20 
ACN to prevent the amidite solution from being too rich in TEA. 
Phosphoramidite 5 was obtained as a white powder after 
lyophilization from anh. benzene (270 mg, 92 % yield; single 
spot by TLC). This solid was used for the assembly of 
maleimido-oligonucleotide 8 in spite of being slightly impurified 25 
with the phosphine hydrolysis product. Attempts to purify 5 by 
silica gel column chromatography were unsuccessful, because the 
collected fractions were less pure than the material obtained after 
the work-up.  
TLC (DCM/MeOH 19:1): Rf = 0.56; 31P NMR (CDCl3, 121.42 30 
MHz): # 148.2, 148.0 ppm (plus one signal at 14.2 ppm); HRMS 
(ESI, positive mode): m/z 863.3774, calcd. for C46H57N4O9PNa 
[M+Na]+ 863.3755. 
DMT-O-[Protected maleimido]-diol hemisuccinate 6. DMAP 
(3.8 mg, 0.031 mmol) and succinic anhydride (6.4 mg, 0.062 35 
mmol) were added to a solution of alcohol 4 (40 mg, 0.062 
mmol) in anh. pyridine (200 µL). The mixture was reacted at 
room temperature, under an Ar atmosphere, for 15 h, after which 
time TLC analysis showed that the starting material (4) had been 
completely consumed. After removing the solvent in vacuo, and 40 
coevaporation with ACN (3 " 1 mL), the resulting crude was 
dissolved in acid-free DCM (2 mL), and this solution was 
extracted with a 10 % aqueous citric acid solution (3 " 2 mL), 
water (1 " 2 mL), and brine (1 " 2 mL). The organic phase was 
dried over anh. Na2SO4, and solvent removal under reduced 45 
pressure afforded 6 as a whitish solid (45 mg, 98 % yield). 
TLC (DCM/MeOH 19:1): Rf = 0.32; 1H NMR (CDCl3, 400 
MHz): # 7.41 – 7.39 (m, 2H), 7.28 (dd, J = 8.9, 1.4 Hz, 6H), 7.19 
(dd, J = 18.3, 8.1 Hz, 1H), 6.83 (dd, J = 8.9, 1.2 Hz, 4H), 6.29 (s, 
2H), 6.13 (d, J = 8.2 Hz, 1H), 4.35 (s, 2H), 3.79 (s, 6H), 3.78 – 50 
3.70 (m, 2H), 3.23 (dd, J = 9.1, 4.0 Hz, 1H), 3.10 (dd, J = 9.0, 6.8 
Hz, 1H), 2.78 (s, 2H), 2.70 – 2.60 (m, 2H), 2.60 – 2.48 (m, 4H), 
2.45 – 2.38 (m, 2H), 1.67 (d, J = 3.9 Hz, 6H); 13C NMR (CDCl3, 
101 MHz): # 175.2, 174.6, 172.3, 169.5, 158.7, 144.7, 141.0, 
135.9, 130.1, 129.3, 128.2, 128.0, 127.0, 113.3, 87.9, 86.4, 63.6, 55 
62.0, 55.4, 52.6, 48.5, 35.4, 34.3, 29.8, 29.6, 29.1, 15.9 ppm; 
HRMS (ESI, positive mode): m/z 763.2833, calcd. for 
C41H44N2O11Na [M+Na]+ 763.2837, m/z 1503.5780, calcd. for 
C82H88N4O22Na [2M+Na]+ 1503.5782. 
DMT-O-[Protected maleimido]-diol-succinyl-LCAA-CPG 7 60 
(15). LCAA-CPG (100 mg, 71 µmol/g) was introduced in a 2 
mL-polyethylene syringe fitted with a polypropylene disc, 
washed (DCM: 3 " 2 mL, 3 % TCA in DCM: 3 " 2 mL, 20 % 
TEA in DCM: 5 " 5 mL, and acid-free DCM: 5 " 5 mL), and 
thoroughly dried. Compound 6 (21 mg, 0.028 mmol), DMAP (2 65 
mg, 0.014 mmol) and EDC (54 mg, 0.28 mmol) was dissolved in 
a 70:1 (v/v) mixture (710 µL) of anh. pyridine and anh. TEA, 
respectively, and the resulting solution poured into the syringe 
containing the LCAA-CPG. The mixture was gently stirred using 
a shaker under an Ar atmosphere for 3.5 h. The CPG beads were 70 
then filtered, washed (pyridine: 10 mL, MeOH: 20 mL, and acid-
free DCM: 30 mL) and dried. Removal of the DMT group from 
an aliquot of DMT-O-[protected maleimido propanoyl]-N-
succinylserinol-LCAA-CPG showed that the solid matrix (7, 
substitution degree = 31 µmol/g) was suitable for solid-phase 75 
oligonucleotide synthesis. Possible unreacted amines were 
capped by reaction with a 1:1 (v/v) mixture of the Cap A and Cap 
B reagents used at the capping step in solid-phase oligonucleotide 
synthesis (2 h, room temperature), after which time the glass 
beads were filtered, washed (MeOH: 20 mL, acid-free DCM: 30 80 
mL) and dried. 
Oligonucleotides and conjugates. 
5'dGTAC-[protected maleimido monomer]-TAGC 8 (87 % 
yield in the crude, as assessed by HPLC) was purified by HPLC 
at the semipreparative scale. Analytical HPLC: tR = 14.2 min 85 
(Figure 2a); MALDI-TOF MS (negative mode): m/z 2807.1 [M-
H]-, M calcd. for C94H120N32O54P8 2808.6. 
dT5-3'[protected maleimide] 11 (86 % yield in the crude, as 
assessed by HPLC) was purified by HPLC at the semipreparative 
scale. Analytical HPLC: tR = 16.0 min (Figure 2b); MALDI-TOF 90 
MS (negative mode): m/z 1857.4 [M-H]-, M calcd. for 
C66H87N12O41P5 1858.4. 
dGTAC-[maleimido]-TAGC 9 was obtained after deprotection 
of 5'dGTAC-[protected maleimide]-TAGC 8 as described above 
(quantitative deprotection as assessed by HPLC of the crude, 95 
Figure 3a). Analytical HPLC (gradient from 5 to 60 % of B in 30 
min): tR = 12.6 min; MALDI-TOF MS (negative mode): m/z 
2711.1 [M-H]-, M calcd. for C88H112N32O53P8 2712.5. The crude 
was used without further purification in the conjugation reaction. 
dT5-3'[maleimide] 12 was obtained after deprotection of dT5-100 
3'[protected maleimide] 11 as described above (96 % deprotection 
yield as assessed by HPLC of the crude, Figure 3b). Analytical 
HPLC: tR = 14.1 min; MALDI-TOF MS (negative mode): m/z 
1761.4 [M-H]-, M calcd. for C60H79N12O40P5 1762.3. The crude 
was used without further purification in the conjugation reactions. 105 
Conjugate 10 (9 + thiocholesterol). After stirring the conjugation 
reaction mixture overnight, the solvent was removed under 
vacuum, water was added and the insoluble residue was filtered 
(13 mm Syringe Filter 0.2 mm PTFE membrane). C18 HPLC 
analysis of the crude showed virtually complete disappearance of 110 
the peak of T5-3'maleimide (9); C4 HPLC trace of the crude is 
shown in Figure 4a, tR = 19.6 min; MALDI-TOF MS (negative 
mode): m/z 3114.2 [M-H]-, M calcd. for C115H158N32O53P8S 
3114.8. 
Conjugate 13 (12 + biotin). Conjugation reaction time: 1 h. 95 115 
%; conjugation yield (from the HPLC of the crude, Figure 4b): 95 
 6  |  Journal Name, [year], [vol], 00–00 This journal is © The Royal Society of Chemistry [year] 
%. Analytical HPLC: tR = 17.0 min; MALDI-TOF MS (negative 
mode): m/z 2064.4 [M-H]-, M calcd. for C72H100N15O42P5S2 
2065.4. 
Conjugate 14 (12 + glutathione). Conjugation reaction time: 1 h. 
96 %; conjugation yield (from the HPLC of the crude, Figure 4c): 5 
96 %. Analytical HPLC: tR = 12.8 min; MALDI-TOF MS 
(negative mode): m/z 2068.3 [M-H]-, M calcd. for 
C70H96N15O46P5S 2069.4.  
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Abbreviations. ACN=acetonitrile, CNE=2-cyanoethyl, 
DCM=dichloromethane, DIPC=N,N'-diisopropylcarbodiimide, 25 
DMAP=N,N-dimethylaminopyridine, DMF=N,N-
dimethylformamide, Dmf=dimethylaminomethylene 
(dimethylformamidine), DMT=4,4'-dimethoxytrityl, EDC=N-
ethyl-N'-(3-dimethylaminopropyl)-carbodiimide!HCl, LCAA-
CPG=long chain aminoalkyl controlled pore glass beads, 30 
Pac=phenoxyacetyl, TCA=trichloroacetic acid, 
TEA=triethylamine, THF=tetrahydrofuran. 
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